Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.
(Reporting by Sriparna Roy in Bengaluru; Editing by Leroy Leo)
